文献速递瓣膜外科冠心病外科

标准与快速展开式主动脉瓣置换联合心肌血运重建的五年双中心临床结局

Standard versus rapid-deployment aortic valve replacement and concomitant myocardial revascularization: 5-year bi-centre clinical outcomes.
PubMed 文献 · Eur J Cardiothorac Surg · 2022-01-01

这项双中心研究比较了快速展开式(RD)与标准Edwards Magna Ease(ME)心包生物瓣在主动脉瓣置换联合冠状动脉旁路移植术中的五年结局。倾向评分加权分析显示,两组五年生存率无显著差异(RD 93% vs ME 91%,HR 0.89,95%CI 0.38-2.09,P=0.784),RD组跨瓣压差持续较低且手术时间较短,但复合事件累积发生率在未校正分析中偏向ME组(16.1% vs 7.3%,HR 2.38,95%CI 1.03-5.52,P=0.043),校正血运重建变量后差异相似(P=0.067)。

要点

  • RD组较ME组主动脉阻断时间(94 vs 120 min,P<0.001)和体外循环时间(128 vs 160 min,P<0.001)显著缩短。
  • RD组出院及随访期跨瓣压差中位数持续较低(均P<0.001)。
  • 五年生存率两组无显著差异(RD 93% vs ME 91%,HR 0.89,95%CI 0.38-2.09,P=0.784)。

核心结论

  • 在主动脉瓣置换联合冠状动脉血运重建中,RD与ME心包生物瓣提供等效的五年临床和血流动力学结局,尽管RD技术跨瓣压差持续较低且手术时间较短。

研究设计与样本

  • 来自2个欧洲中心共285例患者,按主动脉生物瓣类型分为RD组144例(50.5%)和ME组141例(49.5%),采用倾向评分加权进行数据分析。

主要发现

  • 30天死亡率RD组为2.8%,ME组为5%(P=0.09)。
  • 主动脉阻断时间RD组94 min vs ME组120 min(P<0.001),体外循环时间RD组128 min vs ME组160 min(P<0.001)。
  • 五年生存率RD组93% vs ME组91%(HR 0.89,95%CI 0.38-2.09,P=0.784),无显著差异。
  • 五年复合事件累积发生率RD组16.1% vs ME组7.3%(HR 2.38,95%CI 1.03-5.52,P=0.043),校正血运重建变量后P=0.067。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Clinical outcomes of 2 generations of pericardial bioprostheses in concomitant aortic valve and coronary artery bypass graft surgery were analysed. METHODS: Patients were recruited from 2 European centres and divided into 2 groups based on the type of aortic bioprosthesis used: Edwards Intuity Elite™ rapid-deployment (RD) bioprostheses or standard Edwards Magna Ease (ME). A propensity score weighting approach was used for data analysis. RESULTS: A total of 285 patients were included: 144 (50.5%) in the RD group and 141 (49.5%) in the ME group. Thirty-day mortality was 2.8% (RD) and 5% (ME) (P = 0.09). Significantly shorter times of aortic cross-clamp and cardiopulmonary bypass were observed in the RD cohort [94 vs 120 min (P < 0.001); 128 vs 160 min (P < 0.001)]. The RD group was associated with a lower median transvalvular gradient at discharge and follow-up (both P < 0.001). However, 5-year survival was not different, being 93% in RD patients and 91% in the ME group [hazard ratio 0.89 (95% confidence interval: 0.38-2.09), P = 0.784]. The 5-year cumulative incidence of combined events (including percutaneous coronary interventions, endocarditis, thromboembolic events, rehospitalizations and bleeding) favoured the ME group [16.1% (RD) vs 7.3% (ME)] [hazard ratio 2.38 (95% confidence interval:1.03-5.52), P = 0.043]. However, this turned similar when the Cox model analysis was adjusted for revascularization variables (P = 0.067). CONCLUSIONS: RD and ME pericardial bioprostheses used in concomitant aortic valve replacement and coronary artery revascularization provide equivalent clinical and haemodynamic 5-year outcomes, despite constant lower transvalvular gradients and shorter surgical operating times observed with RD technology.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Bottio T, Piperata A, Guariento A, et al. Standard versus rapid-deployment aortic valve replacement and concomitant myocardial revascularization: 5-year bi-centre clinical outcomes. Eur J Cardiothorac Surg. 2022. PMID: 36190347. doi:10.1093/ejcts/ezac476

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。